Document Detail


An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
MedLine Citation:
PMID:  20848397     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
PURPOSE: Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs.
METHODS: Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting.
RESULTS: Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, respectively. Seventy percent of discontinuation cases were due to adverse events rather than to laboratory abnormalities. Serious adverse events were rare (<1%). Dose modifications were made in 158 patients (51%) on 237 occasions. After adjusting for covariates, older age was a predictor of early discontinuation, whereas HCV genotypes 1-4 and daily ribavirin dose of 1000 mg or more were predictors of dose modification.
CONCLUSIONS: The majority of real-world patients with chronic hepatitis C tolerate acceptably dual therapy and very few discontinue it. Subjective decisions on dose reduction of either compound appears to have a major impact on adherence of patients. There is a need to better define, collect and analyse clinical features which may predict adverse events and safety-related decisions during therapy of chronic hepatitis C.
Authors:
Fabio Tinè; Domenico Graviano; Gandolfo Giannuoli; Salvatore Madonia; Giuseppe Malizia; Salvatore Patti; Salvatore Fasola; Mario Cottone; Gennaro D'Amico;
Related Documents :
10022937 - Orally administered proteases in aesthetic surgery.
16249707 - Predictors of virologic failure in hiv-1-infected patients starting highly active antir...
11454177 - African americans with genotype 1 treated with interferon for chronic hepatitis c have ...
15090887 - Clinical trial methodology and clinical cohorts: the importance of complete follow-up i...
12072597 - What is an appropriate indication for endoscopic papillary balloon dilation?
24581257 - Tunnel volume enlargement after posterior cruciate ligament reconstruction: comparison ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  19     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  1113-23     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 John Wiley & Sons, Ltd.
Affiliation:
Unità operativa di Gastroenterologia e Medicina, Ospedali Riuniti Villa Sofia e Cervello, Palermo, Italy. fabiotinemd@virgilio.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phenolic composition and antioxidant properties of some traditionally used medicinal plants affected...
Next Document:  Inhibitors of hyaluronan export from hops prevent osteoarthritic reactions.